Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
It may not have been pretty, but Regulus Therapeutics raised close to $81 million from its recent IPO and some related transactions.
It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And they did it with a big assist from some major league partners in the biopharma industry.
After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>
Regulus Therapeutics capped a busy week of deal-making with a proposed initial public offering of $57.5 million, which the biotech would use in part to fund work on its pipeline of microRNA drugs now in pre-clinical development for cancer, hepatitis C, cardiovascular and fibrotic diseases.
Regulus Therapeutics has signed a deal to lend its microRNA knowhow to Biogen Idec, looking to develop diagnostics for multiple sclerosis.
Regulus Therapeutics will take in $28 million as part of a new partnership with AstraZeneca ($AZN) involving preclinical work on metabolic diseases, cancer and antherosclerosis.
Regulus Therapeutics has signed up another Big Pharma player to its roster of marquee microRNA partners. AstraZeneca will fork over $28 million in equity and an upfront fee to collaborate on three targets, including a lead program that will be explored for its potential to treat atherosclerosis.
Regulus Therapeutics thinks a recent batch of non-human primate data indicates that it may be on the right path to developing a new treatment for cardiovascular disease. One of the central focuses of
Regulus Therapeutics is working with researchers from the University of California, San Diego School of Medicine to identify new microRNA therapeutics for the treatment of angiogenic diseases.